Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...